TerrAscend (TSNDF) Total Non-Current Liabilities (2020 - 2026)
TerrAscend (TSNDF) reported Total Non-Current Liabilities of $390.5 million for Q1 2026, up 8.97% year-over-year from $358.3 million in Q1 2025, and up 3.18% quarter-over-quarter from $378.4 million in Q4 2025.
TerrAscend (TSNDF) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 7 years of Total Non-Current Liabilities data on file, last reported at $390.5 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $390.5 million, up 8.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $390.5 million (up 8.97% YoY), and the FY2025 annual result was $378.4 million, up 11.51% from the prior year.
- Total Non-Current Liabilities grew to $390.5 million in Q1 2026 per TSNDF's latest filing, from $378.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $390.5 million in Q1 2026 and troughed at $218.8 million in Q4 2023.
- A 5-year average of $319.3 million and a median of $339.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities plunged 32.16% in 2023, then jumped 59.75% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $242.5 million in 2022, then declined by 9.79% to $218.8 million in 2023, then soared by 55.12% to $339.4 million in 2024, then grew by 11.51% to $378.4 million in 2025, then increased by 3.18% to $390.5 million in 2026.
- Business Quant data shows TSNDF's Total Non-Current Liabilities at $390.5 million in Q1 2026, $378.4 million in Q4 2025, and $383.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | TerrAscend | - | - | 34.60 Mn | 390.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 390.48 Mn |
| Dec 31, 2025 | 378.43 Mn |
| Sep 30, 2025 | 383.47 Mn |
| Jun 30, 2025 | 361.96 Mn |
| Mar 31, 2025 | 358.34 Mn |
| Dec 31, 2024 | 339.37 Mn |
| Sep 30, 2024 | 371.36 Mn |
| Jun 30, 2024 | 356.64 Mn |
| Mar 31, 2024 | 224.31 Mn |
| Dec 31, 2023 | 218.78 Mn |
| Sep 30, 2023 | 303.50 Mn |
| Jun 30, 2023 | 292.66 Mn |
| Mar 31, 2023 | 246.20 Mn |
| Dec 31, 2022 | 242.51 Mn |
| Sep 30, 2022 | 274.32 Mn |
| Jun 30, 2022 | 323.25 Mn |
| Mar 31, 2022 | 362.90 Mn |
| Dec 31, 2021 | 286.79 Mn |
| Dec 31, 2020 | -118.94 Mn |